ANO7: A Protein Targeted for Prostate Cancer (G50636)

Target Name: ANO7

NCBI ID: G50636

ANO7

ANO7: A Protein Targeted for Prostate Cancer

ANO7 (Prostate-Cancer Associated Protein 5) is a protein that is expressed in high levels in prostate cancer cells. It is a glycoprotein that is composed of four subunits: A, B, C, and D. ANO7 is known for its role in the development and progression of prostate cancer, and it is currently being targeted as a potential drug target or biomarker.

The ANO7 protein is produced in the normal prostate gland, and it is found in the prostate tissue as well as the urine and blood. It is expressed in high levels in prostate cancer cells, and it has been shown to be involved in the development and progression of prostate cancer.

One of the key functions of ANO7 is its role in cell signaling. It is a potent negative regulator of the androgen receptor (AR), which is a protein that is responsible for regulating the effects of androgens, such as testosterone, on prostate cells. When ANO7 is expressed in prostate cancer cells, it works to inhibit the effects of androgens on these cells, leading to the growth and proliferation of the cancer.

Another function of ANO7 is its role in cell migration. Prostate cancer cells are known for their ability to migrate and invade other tissues, and ANO7 is thought to play a role in this process. It is expressed in high levels in the cells that are responsible for cell migration, and it has been shown to be involved in the development and progression of prostate cancer.

In addition to its role in cell signaling and cell migration, ANO7 is also involved in the regulation of prostate stem cell proliferation. Prostate stem cells are a type of cell that have the ability to develop into all of the different types of cells in the prostate gland, and ANO7 is thought to play a role in the regulation of these cells.

The ANO7 protein is also an attractive biomarker for prostate cancer, as it is often expressed in high levels in the cancer. This makes it a potential target for diagnostic tests and therapies. For example, some studies have shown that ANO7 can be used as a biomarker for prostate cancer, and that it may be able to predict the outcomes of prostate cancer surgery.

In addition to its potential as a drug target or biomarker, ANO7 is also of interest to researchers because of its role in the development and progression of prostate cancer. Many studies have shown that ANO7 is involved in the development of prostate cancer, and that it may be a useful target for therapies that are designed to treat this disease.

Overall, ANO7 is a protein that is of interest to researchers because of its role in the development and progression of prostate cancer. As a potential drug target or biomarker, it is a promising target for therapies that are designed to treat this disease. Further research is needed to fully understand the role of ANO7 in prostate cancer, and to determine its potential as a therapeutic agent.

Protein Name: Anoctamin 7

Functions: Has calcium-dependent phospholipid scramblase activity; scrambles phosphatidylserine, phosphatidylcholine and galactosylceramide (By similarity). Does not exhibit calcium-activated chloride channel (CaCC) activity (PubMed:22075693). May play a role in cell-cell interactions (PubMed:17308099)

The "ANO7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ANO7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets